CES used to be all about consumer electronics, TVs, smartphones, tablets, PCs, and – over the last few years – automobiles.

Gilead Sciences Inc. (NASDAQ: GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV ...

Coffee lovers, is your brew not tasting as good as it used to? It could be that your device needs a good cleaning. Coffee machines are breeding grounds for mineral and calcium deposits as well as ...

Big, bold design meets unbridled performance: the Alienware 16 Area-51 isn't flawless, but it'll easily replace a desktop ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...

Lauren Goodman, a registered nurse at Juliana Clinics in Beverly Hills, says she’s had people traveling from around the US to ...

Dec 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage ...

FOSTER CITY, Calif., December 15, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...